Investigating how a specific protein affects lung disease progression in COPD
The role of endothelial derived Leucine-Rich Alpha-2-Glycoprotein 1 (LRG1) in the pathogenesis of COPD
This study is looking at how a protein called LRG1 affects lung health in people with COPD, especially how damage to blood vessels in the lungs can make symptoms worse, with the hope of finding new ways to help improve breathing for those living with this condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10892656 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called Leucine-Rich Alpha-2-Glycoprotein 1 (LRG1) in the development of chronic obstructive pulmonary disease (COPD). The study aims to explore how damage to blood vessels in the lungs contributes to the worsening of COPD symptoms and lung function. By examining lung tissue from patients and using animal models, researchers hope to uncover mechanisms of vascular dysfunction and its impact on lung health. The ultimate goal is to identify new therapeutic strategies that could improve outcomes for individuals suffering from this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with chronic obstructive pulmonary disease (COPD).
Not a fit: Patients with mild respiratory issues or those without a diagnosis of COPD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow the progression of COPD and improve the quality of life for patients.
How similar studies have performed: Previous research has shown promising results in understanding vascular dysfunction in COPD, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Racanelli, Alexandra Christin — Weill Medical Coll of Cornell Univ
- Study coordinator: Racanelli, Alexandra Christin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.